Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s DREAM Of Diabetes Prevention Claim May Come True, But Not For King

Executive Summary

Results of the Diabetes Reduction Assessment with GlaxoSmithKline's Avandia and King's Altace Medication study could support approval of Avandia for prevention of type 2 diabetes, but Altace did not show a significant effect on development of diabetes

You may also be interested in...



GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak

If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void

GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak

If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void

American College Of Cardiology Scientific Sessions, In Brief

Dual renin-angiotensin system inhibition is better: Combining Novartis' newly approved direct renin inhibitor Tekturna (aliskiren) with the firm's angiotensin receptor blocker Diovan (valsartan) yields better antihypertensive efficacy than either monotherapy. In a 1,797-patient placebo-controlled study, a combination of aliskiren 300 mg and valsartan 320 mg produces significantly greater blood pressure control rates (49.3% reaching <140/90 mmHg vs. 37.4% for aliskiren, 33.8% for valsartan and 16.5% for placebo), "provides significant additional BP lowering of up to 4.5/3.2 mmHg over [aliskiren] or [valsartan] alone and retains the excellent tolerability of [aliskiren] and [valsartan] monotherapy," the abstract states. Other aliskiren data presented at ACC include an analysis showing BP reductions persisted up to four weeks after discontinuation and a comparative study showing that more patients on Tekturna reached their BP goal than on the ACE inhibitor ramipril (61.4% vs. 53.1%, respectively). Novartis is positioning Tekturna for use in combination therapy, building on its potentially complementary mechanism of action...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047621

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel